Mobile Phone Project

Using GPRS mobile phone technology for managing symptoms associated with chemotherapy for colon cancer (The Mobile Phone Project)

The aim of the Mobile Phone Project was to develop a reliable and fully-tested system for managing symptoms associated with chemotherapy for colon cancer, using a mobile phone (provided by the Project) and supporting IT infra-structure.


Sponsor: University of Oxford
EudraCT number: 2009-016459-23
Funded by: GlaxoSmithKline
Endorsed by: Cancer Research UK

Phase II single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome.  The study has been added to the NIHR CRN Portfolio database, study ID: 9476.

In the CHOP-OR trial, we are asking the following two questions:


Sponsor: University of Oxford
EudraCT number: 2009-016846-16

To determine the response rates and toxicity of 6MP with low dose methotrexate in patients with breast, ovarian, fallopian tube or primary serous peritoneal cancer who are known to have a BRCA mutation.

A Phase II Clinical trial in patients with known BRCA Defective Tumours.

6MP is closed to recruitment and is in follow-up.

Study Status

CLOSED to recruitment

Target recuitment:

71 (65 evaluable)


Sponsor: University of Oxford
Funded by: Cancer Research UK


Follow up of FOXFIRE patients and final database lock are now complete. Thank you to all sites for their support in reaching these milestones. 2017 will be an exciting year as the results of the study are analysed, presented and published.


EudraCT number: 2010-020621-40
Sponsor: University of Oxford
Funded by: Oxford Biomedical Research Centre

A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer.

The chief aim of the trial is to investigate the safety and the activity of the radiosensitising drug, Nelfinavir, administered before and during radiotherapy in patients with rectal carcinoma.


EudraCT number: 2004-003836-77
Sponsor: University of Oxford
Funded by: Cancer Research UK
Esomeprazole supplied by: Astra Zeneca


Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomised Phase III trial. 

The study has received a favourable opinion from ethics.

To determine the effect of adding WBRT to local treatment on distant intracranial control (primary), quality of life (QoL), performance status, neurocognitive function (NCF) and overall survival.

Study Status

Open to recruitment

Number of active sites: 9
Target recruitment: 200 (20 patients in the UK)


About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.
Subscribe to Department of Oncology RSS